Amedisys Inc (NASDAQ:AMED) (TREND ANALYSIS) shares were traded with a volume more than two times higher than the usual volume. The stock closed last trading session at $42.34, up by 3.44%, with a volume of 765,799 shares against an average volume for the last 3 months of 237,825.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Amedisys Inc (NASDAQ:AMED) stock is currently trading 1.49% below its 52-week-high, 219.55% above its 52-week-low. The 1-year stock price history is in the range of $13.25 – $42.98. Amedisys Inc (AMED) has a price to book ratio of 3.76 versus Healthcare sector average of 123.65. AMED stock price has outperformed the Nasdaq by 37.1%. The Healthcare Services company is currently valued at $1.43 billion and its share price closed the last trading session at $42.34. The stock has a 50-day moving average of $32.18 and a 200-day moving average of $28.87.
Amedisys Inc (AMED) current short interest stands at 0.93 million shares. It has increased by 1% from the same period of last month. Around 4% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.36 million shares, the number of days required to cover the short positions stand at 2.7 days.
The company is expected to announce next quarter earnings on July 29, at consensus estimate of $0.33. Amedisys Inc (AMED) reported last quarter earnings on April 29. The Healthcare Services company announced earnings per share of $0.3 against a consensus Street estimate of $0.2, beating the average estimate by $0.1. This corresponds to an increase of $0.27 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently nine analysts that cover Amedisys Inc stock. Of those nine, three have a Buy rating, five have a Hold rating and one has a Sell rating. On a consensus basis this yields to a Hold rating. The consensus target price stands at $35.83.
A recent analyst activity consisted of Jefferies upgrading their Hold rating to Buy on June 19. Jefferies set their price target at $48. This corresponds to a 13.37% upside from the last closing price. On the date of report, the stock closed at $42.34.
Deutsche Bank upgraded their Hold rating to Buy on June 9, and increased their price target on AMED stock from $28 to $41. This corresponds to a 3.16% downside from the last closing price. On the date of report, the stock closed at $36.11.
Another research firm was SunTrust Robinson Humphrey who upgraded their Neutral rating to Buy on May 27. SunTrust Robinson Humphrey increased their price target on Amedisys Inc from $31 to $36. This translates to a 14.97% downside from the last closing price. On the date of report, the stock closed at $31.67.
Amedisys, Inc. is a multi-regional provider of alternate-site health care services. The Company offers home health care nursing, home infusion therapy, and ambulatory surgery centers. Amedisys operates offices within a network of subsidiaries in the southern and southeastern United States.